Flualprazolam (Item No. 24481) is an analytical reference material categorized as a benzodiazepine. This product is intended for research and forensic applications.
Flualprazolam is structurally related to the triazolo-benzodiazepine, alprazolam. As a class of drugs, benzodiazepines produce central nervous system (CNS) depression and are commonly used to treat, panic disorders, anxiety, and insomnia. The United States Food and Drug Administration has not approved flualprazolam for therapeutic use.
Illicit Uses:
Flualprazolam is generally abused for its sedative/hypnotic effects. Reports from online drug user forums describe it to be similar to clonazepam and alprazolam.
User Population: Flualprazolam is used as a recreational substance in the United States. It is generally abused by young adults, especially males.
Flualprazolam is a 1,2,4-triazolobenzodiazepine. It is structurally similar to alprazolam (of which it is the 2-fluoro derivative),triazolam (replaces the chlorine of triazolam with fluorine at the 2-position on the phenyl ring),and flubromazolam(replaces bromine with chlorine at the 8-positionon the benzodiazepine moiety). It was first developed and patented in 1976.
Biotechnological Applications
Flualprazolam, a 2′-fluoro derivative of alprazolam, is a benzodiazepine sold as designer drug on the illicit drug market.
Flualprazolam is a tranquilizer of the triazolobenzodiazepine (TBZD) class, which are benzodiazepines (BZDs) fused with a triazole ring. It was first synthesised in 1976, but was never marketed. It has subsequently been sold as a designer drug, first being definitively identified as such in Sweden in 2018. It can be described as the 2'-fluoro derivative of alprazolam, or the fluoro instead of chloro analogue of triazolam, and has similar sedative and anxiolytic effects.
Room Temperature in continental US; may vary elsewhere.
Flualprazolam is an agonist at thebenzodiazepine siteof the gamma-aminobutyric acid (GABAA) receptor. Its pharmacological effects are similar to those of other benzodiazepines, such as alprazolam，which is currently controlled under the Convention on Psychotropic Substances of 1971.
User reports have indicated that flualprazolam depresses central nervous system function, with effects such as sedation, loss of memory and disinhibition,similar to other benzodiazepines.
Flualprazolam is banned in Sweden, also is illegal in the UK. In December 2019, the World Health Organization recommended flualprazolam for international scheduling as a Schedule IV medication under the Convention on Psychotropic Substances.
